A
0.136
-0.01 (-9.67%)
| Previous Close | 0.150 |
| Open | 0.142 |
| Volume | 56,824,261 |
| Avg. Volume (3M) | 73,990,428 |
| Market Cap | 35,914,492 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -38.91% |
| Operating Margin (TTM) | -604.96% |
| Diluted EPS (TTM) | -0.300 |
| Quarterly Revenue Growth (YOY) | 28.30% |
| Total Debt/Equity (MRQ) | 626.29% |
| Current Ratio (MRQ) | 2.02 |
| Operating Cash Flow (TTM) | -107.85 M |
| Levered Free Cash Flow (TTM) | -30.50 M |
| Return on Assets (TTM) | -14.19% |
| Return on Equity (TTM) | -275.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Adaptimmune Therapeutics plc | Mixed | Mixed |
AIStockmoo Score
| Value 35% | -3.1 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -3.1 |
| Timing 35% | 1.0 |
| AI Technical info | NA |
| Technical Oscillators info | 0.0 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -17.9% |
| Pillar Agreement | ×1.01 |
| Not in score | |
| Price Volatility info | -0.5 |
| Final Score | -0.90 |
Select this tab to load the latest available analysis.
|
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 44.16% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |